With orders for data now in hand, we have begun ramping up the commercial activities necessary to fulfill those orders. Our network of clinics is growing, and the variety and diversity of datasets available to us is expanding.
PALO ALTO, Calif. (PRWEB) January 05, 2021
maiData Corporation today announced that it has begun commercial operations with its first customer orders for data. The company will immediately begin the construction of custom-curated data sets for use by AI Companies in the training, testing and regulatory approval of their AI algorithms, and in the marketing and education necessary to translate their algorithms into clinical practice.
“We are very pleased to announce that our company has progressed so rapidly into commercial operations,” said Julian Marshall, CEO of maiData. “With orders for data now in hand, we have begun ramping up the commercial activities necessary to fulfill those orders. Our network of clinics is growing, and the variety and diversity of datasets available to us is expanding.”
maiData’s approach to the provision of clinical data for algorithm development is focused on increasing the availability of datasets with broad geographic, socioeconomic and racial/ethnic diversity. The company believes that by helping AI companies obtain data that is a better representation of the population, the algorithms that result will be more generally applicable to patients of all walks of life. Serving as the bridge between clinical data sources and medical AI developers, maiData accelerates AI innovation and deployment.
“maiData is developing a clinical network that will help AI companies reduce some of the selection bias that creeps into their algorithms. Companies tend to collect data from a few of their favorite sites because it is simply easier. We are going to help companies reduce that bias by offering data from many regions,” continued Marshall.
About maiData Corporation: maiData Corporation is a new Silicon Valley startup company. maiData fulfills its mission of “Bringing A.I. to Life” by focusing on helping developers improve the quality and generalizability of their algorithms and helping CROs expand the scale of the clinical studies they can perform.